The ALIGN-AR Trial: Two-Year Outcomes of Transcatheter Aortic Valve Replacement With JenaValve TrilogyTM in High Surgical Risk Patients With Moderate-to-Severe or Severe Native Aortic Regurgitation

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Institutional Grant Support - Edwards Lifesciences; Medtronic
• Grant Support/Research Contract - JenaValve; Boston Scientific Corporation
• Consultant Fee/Honoraria/Speaker's Bureau - Philips; 4C Medical